Intralesional and topical treatments for Peyronie's disease: a narrative review of current knowledge.
Journal
Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132
Informations de publication
Date de publication:
23 Aug 2024
23 Aug 2024
Historique:
received:
17
12
2023
accepted:
27
05
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
Peyronie's disease (PD) presents a multifaceted challenge in contemporary urological practice, marked by penile deformity, pain, and the potential for erectile dysfunction. We meticulously explored the existing literature of intralesional/topical interventions, aiming to provide clinicians with a nuanced understanding of available options for comprehensive PD management. To conduct this review, we performed a systematic search using the PubMed, Scopus, and ScienceDirect databases, including the keywords of combination of the "Peyronie's disease/plastic induration of the penis (PIP) and intralesional/topical treatments". The study selection was based on adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, resulting in the inclusion of 16 articles. We delve into the effectiveness and safety profiles of collagenase Clostridium histolyticum (CCH), interferon, platelet-rich plasma (PRP), hyaluronic acid, botulinum toxin, stem cell, extracorporeal shock wave therapy (ESWT), and traction therapy, assessing their impact on penile curvature, length improvement, and patient-reported symptoms and outcomes. The best options evaluated are intralesional injections of CCH and penile traction devices, alone or in combination. Despite PD remains a challenge for urologists, the objective of this review is to contribute to the evolving landscape of PD management, fostering informed decision-making, and personalized care for individuals grappling with this challenging condition.
Identifiants
pubmed: 39177048
doi: 10.4103/aja202460
pii: 00129336-990000000-00232
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Copyright: ©The Author(s)(2024).
Références
Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14;406–10.
Dunsmuir WD, Kirby RS. Francois de LaPeyronie (|y1978-1747):the man and the disease he described. Br J Urol 1996;78;613–22.
Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, et al. Epidemiology of Peyronie's disease. Int J Impot Res 2002;14;379–83.
Di Maida F, Cito G, Lambertini L, Valastro F, Morelli G, et al. The natural history of Peyronie's disease. World J Mens Health 2021;39;399–405.
Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, et al. The chronology of depression and distress in men with Peyronie's disease. J Sex Med 2008;5;1985–90.
Sandean DP, Lotfollahzadeh S. Peyronie disease. In:StatPearls Treasure Island (FL) StatPearls Publishing;2023. Available from:https://www.ncbi.nlm.nih.gov/books/NBK560628/ [Last accessed on 2023 Nov 27].
Martinez D, Ercole CE, Hakky TS, Kramer A, Carrion R. Peyronie's disease:still a surgical disease. Adv Urol 2012;2012;206284.
Capogrosso P, Pozzi E, Russo GI, Hatzichristodoulou G, Cocci A, et al. Patients'attitude with surgery for Peyronie's disease:results from a multicentric European study. J Sex Med 2023;21 qdad145.
Salonia A, Bettocchi C, Capogrosso P, Carvalho J, Corona G, et al. EAU Guidelines on Sexual and Reproductive Health Arnhem:EAU Guidelines Office;2023. Available from:https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/penile-curvature. [Last accessed on 2023 Nov 27].
Li EV, Esterquest R, Pham MN, Panken EJ, Amarasekera C, et al. Peyronie's disease:pharmacological treatments and limitations. Expert Rev Clin Pharmacol 2021;14;703–13.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:explanation and elaboration. BMJ 2009;339;b2700.
Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, et al. Penile traction therapy and vacuum erection devices in Peyronie's disease. Sex Med Rev 2019;7;338–48.
Cocci A, Cito G, Urzì D, Minervini A, Di Maida F, et al. Sildenafil 25 mg ODT +collagenase Clostridium hystoliticum versus collagenase Clostridium hystoliticum alone for the management of Peyronie's disease:a matched-pair comparison analysis.italic> J Sex Med 2018;15;1472–7.
Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, et al. Long-term safety and curvature deformity characterization in patients previously treated with collagenase Clostridium histolyticum for Peyronie's disease. J Urol 2020;203;1191–7.
Nguyen HM, Anaissie J, DeLay KJ, Yafi FA, Sikka SC, et al. Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie's disease. J Sex Med 2017;14;1220–5.
Anaissie J, Yafi FA, Traore EJ, Sikka SC, Hellstrom WJ. Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie's disease. Andrology 2017;5;274–7.
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, et al. Peyronie's Disease:AUA Guideline 2015. Available from:https://www.auanet.org/guidelines-and-quality/guidelines/non-oncology-guidelines. [Last accessed on 2023 Aug 14].
Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque:a long-term single-blind study. Urology 1998;51;620–6.
Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease:a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41;467–71.
Bellorofonte C, Ruoppolo M, Tura M, Zaatar C, Tombolini P, et al. Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital Urol Nefrol Androl 1989;61;417–22.
Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease. Int J Impot Res 2016;28;161–6.
Mills SA, Gelbard MK. Sixty years in the making:collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond. World J Urol 2020;38;269–77.
Hellstrom WJ, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, et al. Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie's disease:results of a multi-institutional analysis. J Urol 2019;201;777–82.
Sigalos JT, Li MK, Yoffe DA, Modiri N, Hu MY, et al. Acute lower back pain after intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease. J Urol 2022;208;872–7.
Farrell MR, Ziegelmann MJ, Levine LA. Minimally invasive therapies for Peyronie's disease:the current state of the art. Transl Androl Urol 2020;9 Suppl 2:S269–83.
Jain S, Mavuduru RM, Agarwal MM, Singh SK, Mandal AK. Re:clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2014;191;561–3.
Cocci A, Russo GI, Briganti A, Salonia A, Cacciamani G, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease:development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int 2018;122;680–7.
El-Khatib FM, Osman MM, Kopelevich A, Towe M, Yafi FA. Treatment-related outcomes for patients with atypical Peyronie's disease using xiaflex injections. Urology 2020;143;153–8.
Li MK, Sigalos JT, Yoffe DA, Modiri N, Hu MY, et al. Multiple courses of intralesional collagenase injections for Peyronie disease:a retrospective analysis. J Sex Med 2023;20;200–4.
Cocci A, Russo GI, Salonia A, Cito G, Regis F, et al. Predictive factors of patients'and their partners'sexual function improvement after collagenase Clostridium histolyticum injection for Peyronie's disease:results from a multi-center single-arm study.J Sex Med 2018;15;716–21.
Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup:results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int 2015;116;650–6.
Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, et al. The natural history of Peyronie's disease:an ultrasonography-based study. Eur Urol 2008;53;644–50.
Levine L, Rybak J, Corder C, Farrel MR. Peyronie's disease plaque calcification –prevalence, time to identification, and development of a new grading classification.J Sex Med 2013;10;3121–8.
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie's disease:results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013;10;2815–21.
Inal T, Tokatli Z, Akand M, Özdiler E, Yaman Ö. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease:a randomized and prospective study. Urology 2006;67;1038–42.
Sokhal AK, Jain NK, Jhanwar A, Singh K, Saini DK. Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease. Urol Ann 2018;10;154–8.
Kim WW. History and cultural perspective Park NC, Kim SW, Moon DG Penile Augmentation. Berlin:Springer Berlin Heidelberg;2016 11–25.
Sultana A, Grice P, Vukina J, Pearce I, Modgil V. Indications and characteristics of penile traction and vacuum erection devices. Nat Rev Urol 2022;19;84–100.
Elliott S. Re:penile traction therapy with the new device “Penimaster PRO”is effective and safe in the stable phase of Peyronie's disease:a controlled multicentre study. J Urol 2020;204;178.
Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, et al. Penile traction therapy with the new device “Penimaster PRO”is effective and safe in the stable phase of Peyronie's disease:a controlled multicentre study. BJU Int 2019;123;694–702.
Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase Clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease.J Sex Med 2019;16;891–900.
Joseph J, Ziegelmann MJ, Alom M, Savage J, Köhler TS, et al. Outcomes of RestoreX penile traction therapy in men with Peyronie's disease:results from open label and follow-up phases. J Sex Med 2020;17;2462–71.
Dell'Atti L, Ronchi P. Low-intensity laser diode plus extracorporeal shock wave therapy:a new treatment strategy in the management of Peyronie's disease. World J Urol 2023;41;2563–8.
Longo L, Longo D. Laser photobiomodulation of the induratio penis plastica or La Peyronie's syndrome. Photobiomodul Photomed Laser Surg 2022;40;287–91.
Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates:from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009;27;158–67.
Achraf C, Abdelghani PA, Jihad PE. Platelet-rich plasma in patients affected with Peyronie's disease. Arab J Urol 2023;21;69–75.
Karakose A, Yitgin Y. A new alternative approach to management of acute phase Peyronie's disease:low intensity extracorporeal shockwave therapy and platelet-rich plasma. Minerva Urol Nephrol 2024;76;367–72.
Wang N, Tytell JD, Ingber DE. Mechanotransduction at a distance:mechanically coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol 2009;10;75–82.
Di Mauro M, Russo GI, Della Camera PA, Di Maida F, Cito G, et al. Extracorporeal shock wave therapy in Peyronie's disease:clinical efficacy and safety from a single-arm observational study. World J Mens Health 2019;37;339.
Spirito L, Manfredi C, La Rocca R, Napolitano L, Preto M, et al. Long-term outcomes of extracorporeal shock wave therapy for cute Peyronie's disease:a 10-year retrospective analysis. Int J Impot Res 2024;36;135–9.